NCI Division of Cancer Prevention

Research Program Focus Areas and Funding Opportunities for Investigator-initiated Research

NIH NATIONAL CANCER INSTITUTE

Vikrant Sahasrabuddhe, MBBS, DrPH
Division of Cancer Prevention
vikrant.sahasrabuddhe@nih.gov
https://prevention.cancer.gov



- The Division of Cancer Prevention (DCP) is the extramural division of the National Cancer Institute (NCI) devoted to cancer prevention research.

- DCP leads, promotes, and supports rigorous, innovative cancer prevention research and training to reduce the risk, burden, and consequences of cancer for all people.

- DCP research covers the spectrum of cancer prevention research including early detection, screening, prevention/interception, symptom management and supportive care activities.

https://prevention.cancer.gov

NIH NATIONAL CANCER INSTITUTE
Division of Cancer Prevention

Making cancer prevention possible

https://prevention.cancer.gov

Cancer Biomarkers

Research to identify, develop and validate biomarkers for early cancer detection and risk assessment.

Early Detection

Research on the effectiveness and clinical impact of early detection technologies and practices.

Community Oncology and Prevention Trials

Clinical oncology trials in cancer prevention and control in community settings.

Biometry

Supports research in biostatistical, clinical trial, and epidemiological methodologies and mathematical modeling of processes relevant to cancer prevention.

Chemopreventive Agent Development

Research on cancer preventive agent development, from preclinical studies to initiation of phase I clinical trials.

Nutritional Science

Understanding how diet and food components affect cancer risk and tumor cell behavior.

Breast and Gynecologic Cancer

Prevention and early detection of breast, cervix, endometrial and ovarian cancers and their precursors.

Prostate and Urologic Cancer

Conducts and supports research on the prevention and early detection of prostate, bladder, and skin cancers.

Lung and Upper Aerodigestive Cancer

Conducts and supports research on the prevention and early detection of lung and head and neck cancers.

Gastrointestinal and Other Cancers

Prevention and early detection of colorectal, esophageal, liver, pancreas and hematolymphoid cancers.

DCP-supported preclinical and clinical research networks/programs

PREVENT Cancer Preclinical Drug Development Program (PREVENT)

The peer-reviewed research pipeline supports new prevention interventions and biomarkers headed toward clinical trials.

Cancer Prevention Clinical Trials Network (CP-CTNet)

Research Centers develop and conduct early phase clinical trials to assess the preventive potential of agents and interventions of varying classes.

US-Latin American–Caribbean HIV/HPV-Cancer Prevention Clinical Trials Network (ULACNet)

Partnership Centers will focus on improving prevention of human papillomavirus (HPV)-related cancers in human immunodeficiency virus (HIV)-infected individuals.

Supportive Care and Symptom Management

Clinical trials and grant-funded projects examine symptoms and morbidities related to cancer and its treatment, with a focus on interventions to improve quality of life.



NCI Community Oncology Research Program (NCORP)

A clinical trials network of cancer professionals brings research to diverse populations across the country in the communities where most patients live.

DCP-supported early detection/screening and translational research networks/programs

Liquid Biopsy Consortium

A partnership with academic and industrial laboratory teams developing noninvasive liquid biopsy techniques to detect early stage cancer from biomarkers in blood, urine and sputum.

Pancreatic Cancer Detection Consortium (PCDC)

Research teams develop and test new molecular and imaging biomarkers to detect early stage pancreatic ductal adenocarcinoma and its precursor lesions.

Small Cell Lung Cancer (SCLC) Consortium

Six investigators conduct research to expand the understanding of the critical molecular changes in the lung that precede the development of frank SCLC and/or to identify populations at particularly high risk for SCLC.

Alliance of Glycobiologists for Cancer Research

Tumor Glycomics Laboratories work to reveal cancer-related dynamics of complex carbohydrates.

Translational Liver Cancer (TLC) Consortium



Five Translational Research Centers conduct studies to improve surveillance of liver cancer in high-risk populations, increase detectability at early stages, and stratify at-risk patients.

Consortium for Imaging and Biomarkers (CIB)



Research Units integrate imaging strategies with biomarkers to improve cancer screening, early detection of aggressive cancer, assessment of cancer risk, and diagnosis of early stage cancer.



Early Detection Research Network (EDRN)

Labs and centers bring together comprehensive infrastructure and resources critical to discovery, development and validation of biomarkers for cancer risk and early detection.

Consortium for Molecular Characterization of Screen-Detected Lesions

Seven laboratories and a coordinating center focus on identifying screening-detected pre-cancers and early cancers, including within the tumor microenvironment.

NCI Cervical Cancer 'Last Mile' Initiative

A public private partnership between several stakeholders to validate self-sampling as a comparable (non-inferior) alternative to provider-collected sampling for HPV testing in cervical cancer screening.

NLST National Lung Screening Trial NATIONAL CANCER INSTITUTE

NATIONAL CANCER INSTITUTE PLCO Prostate, Lung, Colorectal, & Ovarian CANCER SCREENING TRIAL

DCP-supported research via Cancer Moonshot℠



https://www.cancer.gov/moonshot

https://prevention.cancer.gov

DCP Focus Areas for Investigator-initiated Research Studies on Cancer Prevention

- Early Detection Biomarkers
- Cancer Screening
- Nutrition and Cancer Prevention
- Cancer Prevention/Interception Interventions
- Community Oncology and Supportive Care/Symptom Management

https://prevention.cancer.gov

DCP Focus Areas for Investigator-initiated Research Studies: *Early Detection Biomarkers*

- Discovery, development, and validation of biomarkers (e.g., molecular and imaging) for cancer prevention through screening and risk assessment
- Identification and surveillance of individuals with predisposing conditions or syndromes for the development of pre-invasive or invasive malignancies
- Discovery of tools, technologies, and algorithms to improve accuracy of discrimination among benign vs. malignant lesions or among indolent vs. aggressive early cancers

For more information, please email Sudhir Srivastava, PhD, MPH srivasts@mail.nih.gov

DCP Focus Areas for Investigator-initiated Research Studies: *Early Detection Biomarkers*

Advancing Translational and Clinical Probiotic/Prebiotic and Human Microbiome Research	PA-18-902 (R01 Clinical Trial Optional)
Basic and Translational Research on Adducts in Cancer Risk Identification and Prevention	PAR-19-251 (R01 Clinical Trial Optional)
Basic and Translational Research on Adducts in Cancer Risk Identification and Prevention	PAR-19-252 (R21 Clinical Trial Optional)
Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research	PAR-19-113 (R01 Clinical Trial Optional)
Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Aggressive Cancer	PAR-19-264 (R01 Clinical Trial Optional)

For more information, please email Sudhir Srivastava, PhD, MPH srivasts@mail.nih.gov

https://prevention.cancer.gov

DCP Focus Areas for Investigator-initiated Research Studies: *Early Detection Biomarkers*

Notice of Special Interest (NOSI): Advancing Head and Neck Cancer Early Detection Research (AHEAD)	NOT-CA-20-031
Notice of Special Interest (NOSI): Leveraging Real-World Imaging Data for Artificial Intelligence-based Modeling and Early Detection of Abdominal Cancers	NOT-CA-21-028
Notice of Special Interest (NOSI): Single-Cell Proteomics for Interrogating Premalignant and Early Malignant Lesions	NOT-CA-20-044
Program to Assess the Rigor and Reproducibility of Extracellular Vesicle-Derived Analytes for Cancer Detection	PAR-20-053 (R01 Clinical Trial Not Allowed)
Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes	PAR-20-277 (R21 Clinical Trials Not Allowed)
Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes	PAR-20-276 (R01 Clinical Trial Not Allowed)

For more information, please email Sudhir Srivastava, PhD, MPH srivasts@mail.nih.gov

https://prevention.cancer.gov

DCP Focus Areas for Investigator-initiated Research Studies: *Cancer Screening*

- Clinical trials of screening modalities and management of screen positives, with defined clinical endpoints as well as secondary analyses of clinical trial and observational study data and biospecimens.

- Development of epidemiological approaches for evaluation of the performance characteristics and/or clinical effects of early detection modalities and the development of methodologic approaches for the design and analysis of screening trials.

- Early small-scale evaluation studies and definitive prospective evaluation studies to evaluate clinical effectiveness via assessment of the benefits (including mortality reduction) and associated harms consequent to cancer screening/early detection

For more information, please email Paul Pinsky, PhD at pinskyp@mail.nih.gov

https://prevention.cancer.gov

DCP Focus Areas for Investigator-initiated Research Studies: *Nutrition and Cancer Prevention*

- Research on diet, nutrition, eating behaviors, energy balance, obesity, exercise, food quality, food preparation, food processing, diet therapies and nutritional agents as they relate to prevention, initiation, and recurrence of cancer.

- Diet related studies on understanding of genetic, age-related, and environmental factors that contribute to variation in response to foods and food components at a molecular level.

- Quality of measurements of dietary intake and physical activity including technological and methodological improvements of novel assessment approaches and methods to investigate the patterns and multidimensionality of diet and physical activity behavior with the environmental context of such behaviors

For more information, please email Harold Seifried, PhD at seifrieh@mail.nih.gov

https://prevention.cancer.gov

DCP Focus Areas for Investigator-initiated Research Studies: *Nutrition and Cancer Prevention*

Administrative Supplement for Research on Dietary Supplements (Admin Supp-Clinical Trial Not Allowed)	PA-20-227
Advancing Mechanistic Probiotic/Prebiotic and Human Microbiome Research	PA-18-876 (R01 Clinical Trial Not Allowed)
Diet and Physical Activity Assessment Methodology	PA-18-856 (R01 Clinical Trial Not Allowed)
Diet and Physical Activity Assessment Methodology	PAR-18-857 (R21 Clinical Trial Not Allowed)
Modulating Intestinal Microbiota to Enhance Protective Immune Responses against Cancer	PAR-19-198 (R01 Clinical Trial Not Allowed)
Modulating Intestinal Microbiota to Enhance Protective Immune Responses against Cancer	PAR-19-199 (R21 Clinical Trial Not Allowed)
Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival	PAR-18-893 (R01 Clinical Trial Optional)
Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival	PAR-18-892 (R21 Clinical Trial Optional)
Validation Studies of Analytical Methods for Dietary Supplement Constituents (Admin Supp - Clinical Trial Not Allowed)	PA-20-252

For more information, please email Harold Seifried, PhD at seifrieh@mail.nih.gov

https://prevention.cancer.gov

DCP Focus Areas for Investigator-initiated Research Studies: *Cancer Prevention/Interception Interventions*

- In vitro and in vivo studies utilizing cell lines, organoids, spheroids, and/or animal and computational modeling to evaluate intervention efficacy, toxicity, and biomarkers for their potential in cancer prevention/interception.

- Early phase cancer prevention and/or cancer interception clinical trials (Phases 0, I, and II) that evaluate dietary supplements in pharmacologic ranges, FDA-approved and investigational drugs, small molecules, vaccines, immunomodulators, biologics, biomarkers of efficacy and response, and medical devices and procedures.

- Human studies and/or clinical trials on interventions to prevent and/or intercept the development of pre-cancerous lesions, progression to invasive cancer, recurrence of precancerous lesions, and risk reduction for genetic and non-genetic cancer-predisposing conditions at the individual level.

For more information, please email Brandy Heckman-Stoddard, PhD, MPH at heckmanbm@mail.nih.gov

https://prevention.cancer.gov

DCP Focus Areas for Investigator-initiated Research Studies: *Community Oncology and Supportive Care/Symptom Management*

- Community-based clinical trials in cancer prevention, surveillance, screening, symptom science, translational research, and other activities related to supportive care and prevention of related morbidities.

- Studies on management of toxicities and morbidities in populations undergoing treatment for cancer, including advanced disease, including studies of supportive care for patients and families, and functional outcomes and studies of end-of-life and palliative care

- Ancillary and correlative studies linked to clinical trials supported through the NCI Community Oncology Research Program (NCORP) and the National Clinical Trials Networks (NCTNs)

For more information, please email Worta McCaskill-Stevens, MD, MS at mccaskiw@mail.nih.gov

https://prevention.cancer.gov

DCP Funding Opportunities for Investigator-initiated Clinical Trials on Cancer Prevention

PAR-21-035 Cancer Prevention and Control Clinical Trials Grant Program (R01)



Department of Health and Human Services

Part 1. Overview Information

Participating Organization(s)	National Institutes of Health (NIH)
Components of Participating Organizations	National Cancer Institute (NCI)
Funding Opportunity Title	Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
Activity Code	R01 Research Project Grant
Announcement Type	Reissue of PAR-18-559
Related Notices	See Notices of Special Interest associated with this funding opportunity **January 27, 2021** - Notice of Special Interest (NOSI): Understanding the effects of cancer and cancer treatment on aging trajectories and aging outcomes. See Notice NOT-CA-21-031. • **December 11, 2020** - Notice of Special Interest (NOSI): Tailoring Follow-up Care for Survivors Using Risk-Stratified Pathways. See Notice NOT-CA-21-019.
Funding Opportunity Announcement (FOA) Number	PAR-21-035
Companion Funding Opportunity	PAR-21-033 - National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)
Number of Applications	See Section III. 3. Additional Information on Eligibility.
Catalog of Federal Domestic Assistance (CFDA) Number(s)	93.393, 93.399
Funding Opportunity Purpose	Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for support of investigator-initiated clinical trials related to the programmatic interests of the NCI Division of Cancer Prevention and/or the NCI Division of Cancer Control and Population Sciences that have the potential to reduce the burden of cancer through improvements in early detection, screening, prevention and interception, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health. Applications submitted to this FOA must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see NOT-OD-15-015 for details) and provide specific clinical trial information as described in this FOA and the application instructions. This FOA does not and will not support clinical trials for studies of cancer diagnosis and/or oncologic therapy in patients.

Project Type	• Investigator-initiated clinical trials • IND filed by investigator/institution
Submission deadlines	• General: March 5, July 5, November 5 • AIDS-related: May 7, September 7, January 7
Funding caps	• Not specified; project-specific • Projects with direct costs >$500,000/year any single year require pre-submission discussion via Awaiting Receipt of Application (ARA)

https://grants.nih.gov/grants/guide/pa-files/par-21-035.html

For more information, please email
Brandy Heckman-Stoddard, PhD, MPH at heckmanbm@mail.nih.gov

DCP Funding Opportunities for Investigator-initiated Clinical Trials on Cancer Prevention

PAR-19-356 NCI Clinical and Translational Exploratory/Developmental Studies (R21)



Department of Health and Human Services

Part 1. Overview Information

Participating Organization(s)	National Institutes of Health (NIH)
Components of Participating Organizations	National Cancer Institute (NCI)
Funding Opportunity Title	NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
Activity Code	R21 Exploratory/Developmental Research Grant
Announcement Type	Reissue of PAR-18-020
Related Notices	• **August 24, 2020** - This PAR has been reissued as PAR-20-292. • **March 10, 2020** - Reminder: FORMS-F Grant Application Forms & Instructions Must be Used for Due Dates On or After May 25, 2020- New Grant Application Instructions Now Available. See Notice NOT-OD-20-077. • **August 23, 2019** - Clarifying Competing Application Instructions and Notice of Publication of Frequently Asked Questions (FAQs) Regarding Proposed Human Fetal Tissue Research. See Notice NOT-OD-19-137. • **July 26, 2019** - Changes to NIH Requirements Regarding Proposed Human Fetal Tissue Research. See Notice NOT-OD-19-128.
Funding Opportunity Announcement (FOA) Number	PAR-19-356
Companion Funding Opportunity	None
Number of Applications	See Section III. 3. Additional Information on Eligibility.
Catalog of Federal Domestic Assistance (CFDA) Number(s)	93.393, 93.394, 93.395, 93.396, 93.399
Funding Opportunity Purpose	This Funding Opportunity Announcement (FOA) supports the development of new exploratory research in cancer diagnosis, treatment, imaging, symptom/toxicity, and prevention clinical trials; correlative studies associated with clinical trials; novel cancer therapeutic, symptom/toxicity, and preventive agent development, radiotherapy development activities, and mechanism-driven combinations; innovative preclinical studies, including the use of new clinically-relevant models and imaging technologies, which could lead to first-in-human clinical trials, and therapeutic outcome disparities, including biomarkers or genetic/epigenetic signatures, among diverse racial/ethnic populations, including genetically engineered mouse models, patient-derived xenograft models, organoids, and cell lines. The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (pre-clinical or clinical).

Project Type	• Investigator-initiated exploratory/pilot clinical trials • IND filed by investigator/institution
Submission deadlines	• General: June 21, 2021; October 20, 2021; February 22, 2022; June 21, 2022 • AIDS-related: July 20, 2021; December 17, 2021; March 21, 2022; July 20, 2022
Funding caps	• $275,000 direct costs over 2 years; $200,000 max in one year

https://grants.nih.gov/grants/guide/pa-files/PAR-19-356.html

For more information, please email
Brandy Heckman-Stoddard, PhD, MPH at heckmanbm@mail.nih.gov

https://prevention.cancer.gov

DCP Funding Opportunities for Clinical Trials on Cancer Prevention

Cancer Prevention Clinical Trials Network (CP-CTNet)



Project Type	• UG1/U24 Cooperative Agreement Network • IND filed by investigator/institution or NCI
Submission deadlines	• Investigators can join UG1s led by Lead Academic Organizations (LAOs); submit concepts for approvals; approved concepts move to protocol development and conduct in CP-CTNet sites • Concept submission deadlines every quarter
Funding caps	• Not specified; project-specific • CP-CTNet LAOs and Data Management, Auditing, and Coordinating Center (DMACC) provide clinical trials management support

https://prevention.cancer.gov/cp-ctnet

For more information, please email
Eva Szabo, MD at szaboe@mail.nih.gov

DCP Funding Opportunities for Preclinical studies on Cancer Prevention

PREVENT Cancer Preclinical Drug Development Program (PREVENT)



Project Type	• IND-enabling support (proof-of-concept, secondary testing, advanced preclinical development) via NCI Research and Development Contract resources • IND filed by investigator/institution or NCI
Submission deadlines	• Submission deadlines twice-yearly: second Monday in January and July
Funding caps	• Not specified; project-specific • NCI contracts support generation of data and materials to further advance novel cancer preventive agents or biomarkers toward IND filing and proof-of-principle clinical testing.

https://prevention.cancer.gov/prevent

For more information, please email
Shizuko Sei, MD at seis@mail.nih.gov

NIH/NCI Funding Opportunity Announcements in support of Cancer Prevention*

FOA number	*FOA title*	*FOA weblink*
PA-20-185	NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)	https://grants.nih.gov/grants/guide/pa-files/PA-20-185.html
PAR-20-077	National Cancer Institute Program Project Applications (P01 Clinical Trial Optional)	http://grants.nih.gov/grants/guide/pa-files/PAR-20-077.html
PAR-21-206	Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)	https://grants.nih.gov/grants/guide/pa-files/PAR-21-206.html
PA-21-259 PA-21-260	PHS 2021-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])	https://grants.nih.gov/grants/guide/pa-files/PA-21-259.html https://grants.nih.gov/grants/guide/pa-files/PA-21-260.html https://sbir.cancer.gov/funding

Not an exhaustive list; for illustrative purposes only

NIH NATIONAL CANCER INSTITUTE

Cancer Prevention Fellowship Program

Applications accepted May–August for positi
starting the following June.

Be a part of the program that supports postdoctoral research and professional development, plus offers:

- Competitive stipends, relocation expenses, health insurance benefits, and travel allowances
- Support for up to four years
- Opportunity to earn your MPH, sponsored by NCI
- Research opportunities with experienced NCI mentors
- A cohort of fellows spanning STEM and other fields

cpfp.cancer.gov CPFPCoordinator@mail.nih.gov 240-276-5626

Questions? More Information?
vikrant.sahasrabuddhe@nih.gov

https://prevention.cancer.gov

NATIONAL CANCER INSTITUTE

www.cancer.gov

www.cancer.gov/espanol